SCHEMBL636971

SCHEMBL636971

CC(Cl)OC(=O)O[C@@H]1C[C@H](O[N+](=O)[O-])[C@H](O[N+](=O)[O-])C1

nearest known ligand 0.40

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GSR P00390 9/20 0.40
CA2 P00918 3/20 0.39
BCHE P06276 4/20 0.35
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL636972 1.00 GSR (0.40) GSRCA2BCHEALDH1A1MAPT
SCHEMBL636970 1.00 GSR (0.40) GSRCA2BCHEALDH1A1MAPT
SCHEMBL10157744 1.00 GSR (0.40) GSRCA2BCHEALDH1A1MAPT
SCHEMBL10157762 0.83 GSR (0.33) GSRBCHE
SCHEMBL10157761 0.78 GSR (0.37) GSRCA2BCHE
SCHEMBL10157750 0.78 GSR (0.37) GSRCA2BCHE
SCHEMBL10030646 0.77 BCHE (0.59) GSRCA2BCHEALDH1A1MAPT
SCHEMBL10030647 0.77 BCHE (0.59) GSRCA2BCHEALDH1A1MAPT
SCHEMBL13493922 0.75
SCHEMBL13310181 0.74 GSR (0.38) GSRCA2BCHEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326652-B1 NITRO DERIVATIVES OF FURASEMIDE AND THEIR USE AS DIURETICS MERCK SHARP & DOHME (US) 2014-04-16 EP disclosed
US-8119806-B2 Cicletanine derivatives MERCK SHARP & DOHME CORP. (US) 2012-02-21 US disclosed
US-8119806-B2 Cicletanine derivatives MERCK SHARP & DOHME CORP. (US) 2012-02-21 US disclosed
US-20100029678-A1 DIURETICS MERCK SHARP & DOHME CORP. 2010-02-04 US disclosed
US-20100029678-A1 DIURETICS MERCK SHARP & DOHME CORP. 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029678-A1 DIURETICS NR3C2, REN, NR3C1 GSR 1191/4885CA2 291/4885BCHE 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.